lundi 14 mars 2016

Onco Actu du 14 mars 2016

1. Biologie

Cancer ‘master control switch’ could help tumours hide from immune system [Cancer Research UK]

2. Etiologie

Virility drug may boost skin cancer growth [Universität Tübingen]

4. Dépistage, diagnostic et pronostic

Deep Learning in Medical Imaging: The Not-so-near Future [Diagnostic Imaging]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Genetic Testing Needs To Get Better, And The FDA Wants To Help [Fast Company]

4.2 Dép., diag. & prono. - Génome

Genetic Tests May Not Reveal a Clear Treatment Path for Breast Cancer [NY Times]

5. Traitements

Two-Armed Cancer Killers Emerging to Rival Custom Cell Therapies [Bloomberg]

5.10 Traitements - Essais

‘Unprecedented’ breast cancer trial results explained [Cancer Research UK]

5.2 Pharma

Corvus shoots for $80M in an IPO to support its immuno-oncology pipeline [FierceBiotech]

5.2.1 Pharma - Partenariats

GlaxoSmithKline dumps Five Prime's cancer drug in the midst of Phase I [FierceBiotech]

5.2.3 Pharma - économie

Bristol Bucks Trend Toward Precision Medicine [Wall Street Journal]

5.3 Traitements - FDA, EMA,...

EMA reviews cancer medicine Zydelig [EMA]

5.3.4 Traitements - AMM (FDA, EMA)

XALKORI® (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer [Pfizer]

FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer [FDA]

FDA approves Pfizer's lung cancer drug for expanded use [Reuters]

6.1 Observation

Breast cancer: Double mastectomy rate tripled in 10 years [CNN]

Double mastectomy after breast cancer is pointless for most women, experts find [The Telegraph]

6.11 Patients

Why I gave up my job to go travelling after a double mastectomy [The Guardian]